Advanced Imaging for Pulmonary Fibrosis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Processing failed - manual review needed

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age 18-80 with a diagnosis of chronic hypersensitivity pneumonitis, connective tissue-associated ILD (due to rheumatoid arthritis, systemic sclerosis, mixed connective tissue disease), or undifferentiated ILD.
2. On stable dose immunosuppression treatment (with prednisone, mycophenolate mofetil, mycophenolate sodium, and/or rituximab) for at least 3 months.
3. Pulmonary fibrosis, defined as honeycombing, traction bronchiectasis, or reticular opacities on HRCT performed within 1 year to or at Visit 1.
4. FVC of \>/= 45% and DLCO \>/= 25% predicted on PFTs performed at Visit 1.

Exclusion Criteria:

1. Current or prior exposure to FDA approved anti-fibrotic therapy.
2. Extent of emphysema greater than extent of fibrosis.
3. Pregnancy or plans to become pregnant at baseline or during follow-up.
4. Contraindications to MRI.
5. Contraindications to receiving gadolinium-based contrast agents.
6. Research-related radiation exposure exceeds 50 mSv in the prior year.
7. Estimated glomerular filtration rate (eGFR) \< 30 mL/min (only for individuals with a history of chronic kidney disease).
8. Clinically significant PH defined by use of pulmonary vasodilatory therapy.
9. Respiratory infection within the prior 6 weeks.
10. Smoking of any kind within the prior 6 months.

Where it's running

• Massachusetts General Hospital
  Boston, Massachusetts, United States Recruiting

Study contacts

• Principal investigator: Sydney Montesi, MD — Massachusetts General Hospital
• Study coordinator: Sydney Montesi, MD
• Email: sbmontesi@mgb.org
• Phone: 617 724 4030

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• AccuPulmo CT Portal for Detecting Pulmonary Fibrosis on Chest CT

  This study tests how well the AccuPulmo CT Portal can identify pulmonary fibrosis on existing chest CT scans from adults at Taichung Veterans General Hospital.

  Recruiting Taichung Veterans General Hospital · Taichung · NCT07761377

• Advanced imaging to see how immunosuppression affects lung fibrosis activity

  This trial will test whether immunosuppression changes PET and MRI measurements of active collagen deposition and tissue injury in people with non‑IPF interstitial lung disease who are starting treatment.

  Recruiting Phase 2 Massachusetts General Hospital · Boston, Massachusetts · NCT07572383

• 68Ga-NI-FAPI-04 PET/CT imaging to detect fibroblast activation in cancer, fibrotic, and heart diseases

  This test will see if an injected PET tracer called 68Ga-NI-FAPI-04 can better show fibroblast activation in people with tumors, pulmonary fibrosis, certain autoimmune vascular diseases, hypertrophic cardiomyopathy, or other cardiovascular conditions.

  Recruiting Phase 1/2 Peking Union Medical College Hospital · Beijing, Beijing Municipality · NCT07464132

• Home monitoring for patients with pulmonary fibrosis

  This study tests if using home monitoring and video calls can help people with pulmonary fibrosis manage their condition as well as or better than regular clinic visits.

  Recruiting at 11 sites Erasmus Medical Center · Amsterdam and 10 other locations · NCT06883448

• Understanding genetic and environmental factors in pulmonary fibrosis

  This study looks at how genes and environmental factors affect pulmonary fibrosis to help understand the disease better for people who have it.

  Recruiting Royal College of Surgeons, Ireland · Dublin · NCT06702228

• Identifying biomarkers for progressive pulmonary fibrosis in lung disease patients

  This study is trying to find early signs that can help predict if adults with certain lung diseases will develop progressive pulmonary fibrosis over the next five years.

  Recruiting Amsterdam UMC, location VUmc · Amsterdam, North Holland · NCT06644144

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.